Neurophysiological evaluation of visual function in iRBD: potential role in stratifying RBD conversion risk.

Evoked potentials Neurodegenerative disorders Neurophysiology Parkinson's disease Phenoconversion risk REM sleep Behavior disorder

Journal

Sleep medicine
ISSN: 1878-5506
Titre abrégé: Sleep Med
Pays: Netherlands
ID NLM: 100898759

Informations de publication

Date de publication:
08 2021
Historique:
received: 12 08 2020
revised: 01 03 2021
accepted: 09 05 2021
pubmed: 6 6 2021
medline: 24 8 2021
entrez: 5 6 2021
Statut: ppublish

Résumé

To evaluate neurophysiological alterations of visual function in idiopathic REM sleep Behavior Disorder (iRBD) both as markers and predictors of neurodegenerative disorders. In a longitudinal follow-up study of 46 consecutive iRBD patients (follow-up duration 8.4 ± 3.4 years), the baseline parameters in luminance-contrast pattern (VEPp), red-green color (VEPc) and motion-onset (VEPm) Visual Evoked Potentials in iRBD were compared to early (ePD) and advanced (aPD) Parkinson's Disease subjects. Parameters of latency and amplitude of iRBD converters to neurodegenerative disease were compared with those of the non-converters. The VEP P100 mean latency values for both eyes and for both stimulation checks (30' and 15') were significantly longer in all the three groups of patients as compared to controls; moreover latencies were longer in aPD than in the iRBD group who did not differ from the ePD group. The same held true when we analyzed the number of abnormal subjects belonging to each diagnostic group with a higher number of abnormal subjects in the aPD group compared to both the ePD and in iRBD groups. Chromatic and motion potentials were not different from controls and did not differ in the 3 diagnostic groups. The iRBD subjects who converted to a neurodegenerative disorder showed longer P100 latencies and a higher occurrence of VEPp abnormalities than those who did not convert. Again chromatic and motion VEPs were not different depending on conversion. In iRBD patients the detection of an abnormal VEPp should be considered as a red flag for possible synnucleinopathy, eventually contributing in stratifying the risk of phenoconversion.

Identifiants

pubmed: 34090010
pii: S1389-9457(21)00282-3
doi: 10.1016/j.sleep.2021.05.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

26-31

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Michele Terzaghi (M)

Unit of Sleep Medicine and Epilepsy, IRCCS Mondino Foundation, Pavia, Italy; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy. Electronic address: michele.terzaghi@mondino.it.

Alfredo Romani (A)

Laboratory of Evoked Potentials, IRCCS Mondino Foundation, Pavia, Italy.

Marina Ranzani (M)

Laboratory of Evoked Potentials, IRCCS Mondino Foundation, Pavia, Italy.

Roberto Callieco (R)

Laboratory of Evoked Potentials, IRCCS Mondino Foundation, Pavia, Italy.

Federica Avantaggiato (F)

Laboratory of Evoked Potentials, IRCCS Mondino Foundation, Pavia, Italy.

Riccardo Cremascoli (R)

Unit of Sleep Medicine and Epilepsy, IRCCS Mondino Foundation, Pavia, Italy; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.

Marta Picascia (M)

Laboratory of Neuropsychology/Alzheimer's Disease Assessment Unit, IRCCS Mondino Foundation, Pavia, Italy.

Laura Pilati (L)

Unit of Sleep Medicine and Epilepsy, IRCCS Mondino Foundation, Pavia, Italy; Department of Biomedicine and Clinical Neuroscience, University of Palermo, Italy.

Dario Arnaldi (D)

Clinical Neurology, DINOGMI, University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Valter Rustioni (V)

Unit of Sleep Medicine and Epilepsy, IRCCS Mondino Foundation, Pavia, Italy; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.

Ivana Sartori (I)

C. Munari Center of Epilepsy Surgery, Niguarda Hospital, Milan, Italy.

Roberta Zangaglia (R)

Parkinson's Disease and Movement Disorders Unit, IRCCS Mondino Foundation, Pavia, Italy.

Claudio Pacchetti (C)

Parkinson's Disease and Movement Disorders Unit, IRCCS Mondino Foundation, Pavia, Italy.

Silvia Colnaghi (S)

Laboratory of Evoked Potentials, IRCCS Mondino Foundation, Pavia, Italy.

Maurizio Versino (M)

Neurology and Stroke Unit, ASST Sette Laghi Ospedale di Circolo, Varese; DMC University of Insubria, Varese, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH